三奇汤防治气阴两虚型非小细胞肺癌化疗后骨髓抑制的临床观察

Clinical observation of Sanqi Decoction in the prevention and treatment of myelosuppression induced by chemotherapy in non-small cell lung cancer with syndrome of qi and yin deficiency

目的观察三奇汤防治气阴两虚型非小细胞肺癌化疗后骨髓抑制的临床疗效。方法将60例气阴两虚型非小细胞肺癌患者随机分成治疗组和对照组,每组30例。对照组予以含铂化疗方案,治疗组在化疗基础上加服中药三奇汤。两组化疗疗程均为6周,治疗组提前1周开始服中药(即疗程为7周)。观察骨髓抑制发生率及分级情况,比较血清粒-巨噬细胞集落刺激因子(GMCSF)及生活质量评分(KPS)的变化情况。结果①组间骨髓抑制率比较,治疗组较对照组明显更低(P<0.05)。治疗组WBC、RBC、PLT及NEUT的Ⅰ、Ⅱ度毒性反应发生率均明显少于对照组(P<0.05)。②组间治疗后比较,治疗组GM-CSF水平明显高于对照组(P<0.05)。③组间比较,治疗组KPS提高率及稳定率均明显优于对照组(P<0.05)。结论三奇汤防治气阴两虚型非小细胞肺癌化疗后骨髓抑制效果显著,且可调节相关细胞因子浓度,改善患者的生活质量。

Objective To observe the clinical efficacy of Sanqi Decoction in the prevention and treatment of myelosuppression induced by chemotherapy in nonsmall cell lung cancer with syndrome of qi and yin deficiency. Methods 60 patients of non-small cell lung cancer with syndrome of qi and yin deficiency were randomly divided into the treatment group and control group,30 case in each group. The control group was treated with platinum chemotherapy,and the treatment group was treated with Sanqi Decoction additionally based on chemotherapy. The chemotherapy course of both groups were 6 weeks,and Sanqi Decoction was given one week in advance( a course of 7 weeks in the treatment group). The incidence and classification of myelosuppression were observed,and the serum level of granulocyte macrophage colony stimulating factor( GM-CSF) and Karnofsky performance scores( KPS) were compared. Results ① The incidence rate of myelosuppression in the treatment group was significantly lower than that in the control group( P < 0. 05). The incidence rates of toxic reaction withⅠ、Ⅱ degree on white blood cell( WBC),red blood cell( RBC),platelet( PLT) and neutrophil( NEUT) were significantly lower than those in the control group( P < 0. 05).②After treatment,the level of GM-CSF in the treatment group was significantly higher than that in the control group( P < 0. 05). ③ After treatment,the improvement and stability of KPS in the treatment group were significantly better than those in the control group( P < 0. 05). Conclusion Sanqi Decoction shows significant efficacy in the prevention and treatment of myelosuppression induced by chemotherapy in non-small cell lung cancer with syndrome of qi and yin deficiency,which can regulate the related cytokine concentration and improve the life quality of patients.